DAIC

FEBRUARY 18, 2025

In tricuspid valve regurgitation, a complex condition that Cedars-Sinai experts regularly treat, the valve between two heart chambers on the right side doesn't open or close properly. Makkar explained the advances for patients with tricuspid valve disease in a conversationwith the Cedars-Sinai Newsroom. Image by Getty.

Tricuspid 52

Tricuspid Open-Heart Surgery Quality of Life Anatomy 52

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 111

Tricuspid Bicuspid/Mitral Heart Valves Innovation 111

DAIC

FEBRUARY 2, 2024

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100

Tricuspid Quality of Life Bicuspid/Mitral Innovation 100

DAIC

JUNE 5, 2024

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. Critical Care has made significant contributions to our company and has a long history of pioneering innovation.

Critical Care 105

Critical Care Tricuspid Innovation Bicuspid/Mitral 105

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 52

Tricuspid Bicuspid/Mitral Heart Valves Innovation 52

DAIC

DECEMBER 22, 2023

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Topaz is an innovative, minimally invasive device designed specifically to help patients suffering from severe TR, without the need for open heart surgery.

Tricuspid 59

Tricuspid Pacemaker Heart Valves Open-Heart Surgery 59

DAIC

APRIL 5, 2024

New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis.

Research 52

Research Heart Disease Best Practices Education 52